logo-loader
BioCardia

BioCardia 'validated' by biopharma giant AstraZeneca in exclusive development agreement

BioCardia Inc (OTCMKTS:BCDA) CEO Peter Altman tells Proactive Investors the biotechnology company has signed an extension to a 2017 development agreement with pharma giant AstraZeneca PLC (NYSE:AZN) to use the firm's Helix biotherapeutic delivery catheter system.

Altman says as part of the agreement, BioCardia will have the potential to advance Helix into clinical development with the UK-based company.

Quick facts: BioCardia

Price: £0.00

Market: OTC
Market Cap: £0.00
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Qrons seeking to find a cure for traumatic brain injuries...

Qrons Inc (OTCQB: QRON) CEO Jonah Meer tells Proactive the New York-based biotechnology company is developing two products, one of which involves a 3D-printable scaffold, aimed at helping to treat traumatic brain injuries. Meer says that traumatic brain injuries are the number one cause of...

13 hours, 32 minutes ago

2 min read